


## HIF-2 $\alpha$ -IN-3

<b>Cat. No.:</b>	HY-18370		
<b>CAS No.:</b>	313964-19-1		
<b>Molecular Formula:</b>	C <sub>12</sub> H <sub>6</sub> ClN <sub>5</sub> O <sub>5</sub>		
<b>Molecular Weight:</b>	335.66		
<b>Target:</b>	HIF/HIF Prolyl-Hydroxylase		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 12.5 mg/mL (37.24 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.9792 mL	14.8960 mL	29.7921 mL
5 mM	0.5958 mL	2.9792 mL	5.9584 mL
10 mM	0.2979 mL	1.4896 mL	2.9792 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

HIF-2 $\alpha$ -IN-3, an allosteric inhibitor of hypoxia inducible factor-2 $\alpha$  (HIF-2 $\alpha$ ), exhibits an IC<sub>50</sub> of 0.4  $\mu$ M and a K<sub>D</sub> of 1.1  $\mu$ M. Anticancer agent<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 0.4  $\mu$ M (HIF-2 $\alpha$ )<sup>[1]</sup>  
 KD: 1.1  $\mu$ M (HIF-2 $\alpha$ )<sup>[1]</sup>

#### In Vitro

HIF-2 $\alpha$ -IN-3 (Compound 1) inhibit HIF-2 $\alpha$ -ARNT (also known as HIF- $\beta$ ) heterodimerization by binding an internal cavity of the HIF-2 $\alpha$  PAS-B domain<sup>[1]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Rogers JL, et al. Development of inhibitors of the PAS-B domain of the HIF-2 $\alpha$  transcription factor. J Med Chem. 2013 Feb 28;56(4):1739-47.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA